Podcasts about ADC

Every role rewards a different set of skills and most people climb slower because they're focusing on the wrong ones.In this video we break down the most important fundamentals from Early Game, Mid Game and X-Factor's that actually help you climb in each role: mid, jungle, ADC, top and support.

Simple Scans for Cloud Metadata Service https://isc.sans.edu/diary/Simple%20Scans%20for%20Cloud%20Metadata%20Service/33260 Oracle Critical Security Patch Update Advisory - August 2026 https://www.oracle.com/security-alerts/cspuaug2026.html NetScaler ADC and NetScaler Gateway Security Bulletin for CVE-2026-19489 and CVE-2026-19490 https://support.citrix.com/support-home/kbsearch/article?articleNumber=CTX696939 Beware of Ransomware Rescuers https://www.guidepointsecurity.com/blog/beware-ransom-busters/ My Upcoming Classes https://www.sans.org/profiles/dr-johannes-ullrich

As political activities ahead of the 2027 general election begin to gather momentum, Nigeria's opposition is once again talking about unity. The goal is to present a single presidential candidate capable of challenging President Bola Tinubu.But with key parties and influential figures already expressing different views, many are asking whether that ambition can become a reality.Today on Nigeria Daily, we ask: Can Nigeria's opposition truly unite behind one presidential candidate, or are the cracks already too deep?

En este episodio del pódcast BreastLink de ScienceLink, conducido por el Dr. Juan Carlos Samamé, se analiza el cambio de paradigma en el tratamiento de primera línea del cáncer de mama triple negativo metastásico (CMTNm). Para abordar este tema, se cuenta con la participación del Dr. Alejandro Lara Bañuelas, oncólogo médico adscrito al Instituto Mexicano del Seguro Social (IMSS) y al Centro Estatal de Cancerología de Chihuahua, México, quien se desempeñó como coinvestigador en los ensayos de la plataforma ASCENT. La conversación profundiza en los resultados del estudio fase III ASCENT-04/KEYNOTE-D19, el cual evalúa la combinación de sacituzumab govitecan —un conjugado anticuerpo fármaco (ADC) dirigido contra Trop-2— junto con pembrolizumab en pacientes con CMTNm no tratadas previamente en el escenario avanzado y con CPS ≥10.El Dr. Lara Bañuelas expone el diseño metodológico del ASCENT-04, destacando la inclusión de pacientes vírgenes a tratamiento metastásico o con recaída tras un intervalo libre de enfermedad de al menos seis meses desde la finalización de la terapia con intención curativa. La discusión aborda el beneficio clínicamente significativo observado en la supervivencia libre de progresión (SLP), objetivo primario del estudio, con una diferencia absoluta de tres meses a favor de la combinación frente a la quimioterapia estándar más pembrolizumab. Asimismo, se destaca la duplicación en la duración de la respuesta objetiva, los análisis de subgrupos que confirman el beneficio independiente de los niveles de expresión de Trop-2, estado mutacional de BRCA o estatus HER2 (incluyendo HER2 low y ultra-low), y la persistencia de la eficacia en la supervivencia libre de progresión de segunda línea (SLP2) a pesar del entrecruzamiento (crossover) permitido en el protocolo.En cuanto a los datos de seguridad, el Dr. Lara Bañuelas comparte la experiencia práctica sobre el perfil de toxicidad del esquema sacituzumab govitecan más pembrolizumab, señalando que la neutropenia es el evento adverso más relevante, pero resulta predecible y manejable mediante el uso profiláctico de factores estimulantes de colonias de granulocitos. Finalmente, se contrapone el nicho terapéutico del ASCENT-04 con el del estudio ASCENT-03 en poblaciones con CPS

When a brand says it "used AI," that could mean anything from a tool speeding up a human's first draft to a system generating and shipping work on its own — and almost all of the real risk lives in the difference. So as AI moves deeper into creative work, which decisions are you certain still belong to a human?Real agility here isn't being quick with the latest tools. It's moving fast without losing the through-line that makes a brand recognizable — the ability to know exactly where human judgment stays non-negotiable.Today we're recording live at Ai4 2026 in Las Vegas at the Venetian, and we're going to talk about:- Drawing a clear line between where AI sharpens creative work and where it introduces unacceptable brand risk.- A practical look at how AI was used in a national campaign to improve the creative process, not just automate it.- The strategic shift as consumers move from traditional search engines to AI-powered platforms for discovery and research.To help me dig into this, I'd like to welcome Taryn Crouthers, CEO at Big Spaceship.About Taryn CrouthersTaryn Crouthers is the CEO of Big Spaceship, MSQ Partners' award-winning creative agency. A passionate leader, Taryn has spent her decades-long career inspiring teams to create work that moves both people and business. Her work spans advertising, media, entertainment, and the distribution and commercialisation that scale them. She is the former President of social-first global media company ATTN:, where she helped lead the company from pre-revenue through its $100M acquisition.Along the way, she earned recognition including Campaign's Inspiring Women (2026), 40 Over 40 (2025), Ad Age Leading Women (2024), Cynopsis' Corporate Visionary, and Top Women in Digital.An entrepreneur at heart and a nationally recognised voice on the future of creativity and AI integration, Taryn brings a founder's mindset to scaling creative businesses and developing new revenue models. She has served on juries for Cannes Young Lions, The One Show, ADC, Webby Awards, and other prestigious industry competitions. She serves on the Advisory Board of Miami Ad School and is an active investor in emerging creative and technology-driven companies.She is also a co-founder of the Women in AI Summit for the Creative Community and launched the Women in AI Creative Cohort, which selects 15 top global executives for a six-month AI mentorship program.Taryn Crouthers on LinkedIn---------- Resources ---------- Big SpaceshipThe Agile Brand podcast is brought to you by TEKsystems.We're proud to be a media partner for #MAICON26 - Oct. 13-15! Learn how AI can power your marketing and business and help you grow smarter. Use code AGILE150 to save! Reach your customers with Reddit. Spend $500 in ad spend, get $500 back in ad credit!Chaser is the only Slack-native project management platform that helps teams turn messages into tracked tasks, automate follow-ups, and maintain team-wide visibility, without adopting another tool. Now integrated with Claude and other GenAI tools. Learn more at trychaser.com and use code AGILEBRAND for a 3-month free trial (normal trial is 14 days).The most influential minds in software, AI, and engineering leadership will be at WeAreDevelopers World Congress North America, September 23-25 in San Jose. Start building your own apps with Replit and get $20 off.Enjoyed the show? Tell us more at and give us a rating so others can find the show.Connect with Greg on LinkedInDon't miss a thing: get the latest episodes, sign up for our newsletter and more.Check out The Agile Brand Guide website with articles, insights, and Martechipedia, the wiki for marketing technology.The Agile Brand is produced by Missing Link—a Latina-owned strategy-driven, creatively fueled production co-op. From ideation to creation, they craft human connections through intelligent, engaging and informative content. Hosted on Acast. See acast.com/privacy for more information.

Huw Ware Being Referee Live

When a brand says it "used AI," that could mean anything from a tool speeding up a human's first draft to a system generating and shipping work on its own — and almost all of the real risk lives in the difference. So as AI moves deeper into creative work, which decisions are you certain still belong to a human?Real agility here isn't being quick with the latest tools. It's moving fast without losing the through-line that makes a brand recognizable — the ability to know exactly where human judgment stays non-negotiable.Today we're recording live at Ai4 2026 in Las Vegas at the Venetian, and we're going to talk about:- Drawing a clear line between where AI sharpens creative work and where it introduces unacceptable brand risk.- A practical look at how AI was used in a national campaign to improve the creative process, not just automate it.- The strategic shift as consumers move from traditional search engines to AI-powered platforms for discovery and research.To help me dig into this, I'd like to welcome Taryn Crouthers, CEO at Big Spaceship.About Taryn CrouthersTaryn Crouthers is the CEO of Big Spaceship, MSQ Partners' award-winning creative agency. A passionate leader, Taryn has spent her decades-long career inspiring teams to create work that moves both people and business. Her work spans advertising, media, entertainment, and the distribution and commercialisation that scale them. She is the former President of social-first global media company ATTN:, where she helped lead the company from pre-revenue through its $100M acquisition.Along the way, she earned recognition including Campaign's Inspiring Women (2026), 40 Over 40 (2025), Ad Age Leading Women (2024), Cynopsis' Corporate Visionary, and Top Women in Digital.An entrepreneur at heart and a nationally recognised voice on the future of creativity and AI integration, Taryn brings a founder's mindset to scaling creative businesses and developing new revenue models. She has served on juries for Cannes Young Lions, The One Show, ADC, Webby Awards, and other prestigious industry competitions. She serves on the Advisory Board of Miami Ad School and is an active investor in emerging creative and technology-driven companies.She is also a co-founder of the Women in AI Summit for the Creative Community and launched the Women in AI Creative Cohort, which selects 15 top global executives for a six-month AI mentorship program.Taryn Crouthers on LinkedIn---------- Resources ---------- Big SpaceshipThe Agile Brand podcast is brought to you by TEKsystems.We're proud to be a media partner for #MAICON26 - Oct. 13-15! Learn how AI can power your marketing and business and help you grow smarter. Use code AGILE150 to save! Reach your customers with Reddit. Spend $500 in ad spend, get $500 back in ad credit!Chaser is the only Slack-native project management platform that helps teams turn messages into tracked tasks, automate follow-ups, and maintain team-wide visibility, without adopting another tool. Now integrated with Claude and other GenAI tools. Learn more at trychaser.com and use code AGILEBRAND for a 3-month free trial (normal trial is 14 days).The most influential minds in software, AI, and engineering leadership will be at WeAreDevelopers World Congress North America, September 23-25 in San Jose. Start building your own apps with Replit and get $20 off.Enjoyed the show? Tell us more at and give us a rating so others can find the show.Connect with Greg on LinkedInDon't miss a thing: get the latest episodes, sign up for our newsletter and more.Check out The Agile Brand Guide website with articles, insights, and Martechipedia, the wiki for marketing technology.The Agile Brand is produced by Missing Link—a Latina-owned strategy-driven, creatively fueled production co-op. From ideation to creation, they craft human connections through intelligent, engaging and informative content. Hosted on Acast. See acast.com/privacy for more information.

As reactions and debates continue to trail the omission of primary and secondary school credentials from the educational information published for President Bola Ahmed Tinubu, questions are being raised about who is responsible for verifying the credentials politicians submit when seeking public office.Today on Nigeria Daily, we look beyond the current debate to understand what INEC actually verifies, who is responsible for authenticating politicians' academic credentials, and what happens when questions are raised about a candidate's qualifications.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into recent transformative events that are shaping this dynamic industry, from strategic mergers to groundbreaking drug approvals. Starting with the merger between Supernus Pharmaceuticals and Indivior Pharmaceuticals, this all-stock deal valued at $2.2 billion is set to create a powerhouse focused on central nervous system (CNS) disorders. By combining their resources, the new entity is expected to enhance its capabilities in neurological disorders with a robust portfolio of approved drugs. This merger allows the companies to leverage economies of scale, optimize research and development, and expand their market presence, offering promising prospects for advancements in treating CNS-related conditions. In regulatory news, Novartis has secured FDA approval for an expanded indication of Pluvicto (lutetium vipivotide tetraxetan), a radioligand therapy originally approved for PSMA-positive metastatic castration-resistant prostate cancer. This therapy can now be used for metastatic hormone-sensitive prostate cancer, marking a significant step forward in prostate cancer treatment. By targeting prostate-specific membrane antigen (PSMA) with precision, Pluvicto offers the potential for improved patient outcomes and highlights the growing role of radioligand therapies in oncology. Globally, Pharmamar's Zepzelca (lurbinectedin) has been approved in Canada, Qatar, and South Korea as a first-line maintenance therapy for extensive-stage small cell lung cancer. This approval signifies a potential shift in how aggressive cancer types are treated, particularly when combined with PD-L1 inhibitors, opening new avenues for effective combination therapies. Industry partnerships continue to drive innovation, as seen with Fujifilm and Taiho Pharmaceutical's collaboration to develop next-generation antibody-drug conjugate (ADC) manufacturing technologies using the Aralinq platform. With ADCs becoming increasingly pivotal in targeted cancer therapies due to their precision in delivering cytotoxic drugs to tumor cells, advancements in manufacturing could significantly enhance production capabilities and therapeutic efficacy. Financial dynamics within the industry remain robust. AbbVie has raised its 2026 revenue forecast to $67.6 billion, citing strong performances from its immunology drugs Skyrizi and Rinvoq. These therapies have shown substantial success in treating autoimmune conditions, reflecting their impact on AbbVie's financial health and reinforcing confidence in their commercial viability. On the clinical trial front, Ratio Therapeutics has successfully closed a $70 million Series C funding round to support its radiotherapeutics pipeline and initiate the ATLAS trial. This infusion of funds underscores the continued interest and investment in radiopharmaceuticals with promising applications in oncology. The landscape of mergers and acquisitions remains active as AstraZeneca and Bristol Myers Squibb reportedly engage in early-stage merger discussions. Such a merger could create an oncology giant valued at approximately $400 billion, potentially reshaping competitive dynamics and accelerating innovation across therapeutic areas. Regulatory changes are also underway with HRSA advancing a revised 340B rebate model pilot program despite hospital opposition. The implications for healthcare providers are significant as this could affect operational efficiencies and financial strategies within participating entities. Overall, these developments reflect ongoing trends toward industry consolidation and strategic partnerships that foster innovation in drug manufacturing technologies. Regulatory approvals continue to advance precision medicine through targeted therapies, showcasing the sector's dynamic nature as it addresses unmet medical needs while navigating complex regulatory environments. Meanwhile, Sandoz's settlement of nearly $500 million for antitrust claims in the U.S. highlights ongoing scrutiny of industry competition practices. This settlement signals potential shifts in market dynamics as companies seek to resolve legal challenges while maintaining operational integrity. Cybersecurity has emerged as a critical concern following Amgen's reported breach compromising sensitive patient data. This incident amplifies the need for enhanced data protection measures to safeguard information integral to patient trust and competitive integrity. In leadership news, BioNTech has appointed Guido Oelkers as CEO amid its continued innovation in mRNA technology post-COVID-19. This strategic move underscores BioNTech's commitment to leadership capable of navigating advances in mRNA therapeutics. Lastly, Novo Nordisk faced setbacks with its investigational therapy ziltivekimab failing a phase 3 trial targeting inflammatory pathways for cardiovascular outcomes. Despite such challenges, these high-stakes trials highlight both risks and opportunities inherent in pharmaceutical innovation. As we reflect on these stories, it's clear that scientific advancements, regulatory developments, and strategic business moves continue to shape the trajectory of the pharmaceutical and biotech sectors. These efforts promise significant implications for future drug development and patient care as companies strive to harness breakthroughs while adapting to evolving industry landscapes.Support the show

Jon Treffert was diagnosed with locally advanced muscle-invasive bladder cancer in September 2023. After 2 years of treatment, including surgical resection and 6 months with an antibody-drug conjugate (ADC), he had no evidence of disease and an intact bladder. In this episode, CANCER BUZZ speaks with Treffert about his experience receiving ADCs and how he is using his platform as a patient advocate to support other patients make informed decisions about their bladder cancer care. Guest: Jon Treffert  Bladder Cancer Patient Advocate  Powell, TN "I'm trying to build a community, a cohort of people like myself, who have chosen to keep their bladder, have had a complete response to EVP, and try to share lived experience." —Jon Treffert "One piece of advice I always give is tell your care team anytime you have something that's out of the ordinary." —Jon Treffert Resources: Jon's Story: "I encourage folks to do their own research." Journey to Health blog ACCC Bladder Cancer Resources ACCC Antibody-Drug Conjugate Resources  

As political activities ahead of the 2027 general election begin to gather momentum, Nigeria's opposition is once again talking about unity. The goal is to present a single presidential candidate capable of challenging President Bola Tinubu.But with key parties and influential figures already expressing different views, many are asking whether that ambition can become a reality.Today on Nigeria Daily, we ask: Can Nigeria's opposition truly unite behind one presidential candidate, or are the cracks already too deep?

Listen in to learn from Thomas Bachelot, MD, PhD, and Mafalda Oliveira, MD, PhD, about recent advances and the integration of anti-TROP2 antibody-drug conjugates (ADCs) into the management of patients with triple-negative breast cancer, including as first-line therapy for those who are not eligible for immunotherapy. Experts will cover: The evolving role of TROP2-directed antibody-drug conjugates (ADCs), including sacituzumab govitecan and datopotamab deruxtecan, in addressing unmet needs in the frontline treatment of TNBC.  Treatment sequencing, reimbursement barriers to recent approvals, and toxicity-informed treatment selection considerations. How to monitor and manage ocular and pulmonary toxicities and care-team readiness for implementing ADC-based therapy in routine practice. Presenters:Thomas Bachelot, MD, PhD Medical Oncology Department of Oncology Léon Bérard Center Lyon, France Mafalda Oliveira, MD, PhD Senior Consultant Medical Oncology Department Vall d'Hebron University Hospital Senior Clinical Investigator Breast Cancer Group Vall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus Barcelona, Spain Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Visit the program page for more content associated with this discussion. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This show has been flagged as Clean by the host. Hello, again. This is Trey. Welcome to part 8 in my Cheap Yellow Display (CYD) Project series. If you wish to catch up on earlier episodes, you can find them on my HPR profile page https://www.hackerpublicradio.org/correspondents/0394.html It is hard to believe that I started this project and the HPR series to document it more than a year ago. Time flies. Life happens. I spent the last 8 months so focused on work related activities that I had to set the project aside. And once I set it aside, it was difficult to get back to again. The one time I tried, I found that my son's old Windows laptop, which I had commandeered to use for the project, was once and truly dead. We live in a different world now than we did when I began this project. Today, everything is about AI – how it is changing our world, increasing efficiencies, and even displacing certain types of jobs. "Vibe coding" is transforming the way we make software, and now everyone is a developer. Within my organization, we are all being strongly encouraged to learn more about AI and apply it in our daily work. We are blessed to have access to a wide range of training and to powerful tools which support the process. Several colleagues within my organization and outside my organization have recommended Claude Code -- for development, for organization, for brainstorming, and for much more. My role is not that of a developer, and I have had no need for Claude Code at work. There are plenty of other tools for me to use. But at home, I thought... I could install Claude Code at home to experiment with and to learn. And then it hit me. I wonder if I could use Claude Code to help me with my stalled CYD project. "Hello, my name is Trey, and I am a fraud." OK. I don't think I am a fraud, but having never used such a powerful tool to help me code, I feel a little bit like a fraud, with Claude doing the work for me. Let's talk through what we did. As I mentioned, I was unable to use the laptop on which I created the original GUI code. But no worries, because It was all on GitHub, right? So, I began by trying to install Claude Code on one of my Ubuntu machines. That failed miserably, and all the instructions I found online recommended running it on Windows. So I transitioned to installing Claude Code on a freshly built Windows 10 system using some old hardware which will not support Windows 11. Surprisingly, It seems that Claude wants to run within Ubuntu on Windows Subsystem for Linux (WSL). Once I went through all the hoops for installing and setting up my basic subscription, I got to work. I created a new directory to use for all my project files, and another one for Claude to write all its output files to. Everything I have read and heard about using Claude Code for a project like this recommended beginning by using Claude to create the project plan. So my first prompt was as follows: "I am building a project using an ESP32 cheap yellow display. The final goal is to have a device with a graphical user interface which will allow me store several text messages, each assigned to their own specific button. Then, when one of the buttons is pressed, the message will be converted into morse code, and the message will be sent by blinking an onboard LED. I already have the initial design for the GUI coded in my github repository. Please construct a detailed step by step plan for building this application" I wanted to keep it simple at the beginning, so even though I plan to use an opto-isolated relay for the output, I am starting out using the built in LED. Claude asked me for the URL for my Github repository, and I provided it. After thinking for a bit, it produced a project plan. CYD Morse Sender — Step-by-Step Build Plan What You Already Have - 3 fully designed LVGL screens (Send, Config, Keyboard) - 7 send buttons with green styling on the Send Screen - Speed slider (5–30 WPM) and program slot dropdown on Config Screen - Text area + LVGL keyboard widget on Keyboard Screen - Display driver and touchscreen hardware initialized (but touch read was stubbed out) --- Phase 1: Fix Touchscreen Input Initialize the XPT2046 on VSPI, replace the hardcoded touched = false with real touch data, calibrate raw ADC coordinates to screen pixels, and verify all three nav buttons transition screens correctly. Phase 2: Persistent Message Storage Use Preferences.h / NVS to store 7 messages ("msg0" – "msg6") that survive power cycles. Load on boot and populate send button labels. Phase 3: Config Screen — Slot Selection & Speed Wire the Program dropdown to g_selectedSlot, wire the Speed slider to g_wpm with a live WPM label, and wire the Set button to clear the text area and navigate to the Keyboard Screen. Phase 4: Keyboard Screen — Capture and Save Text On keyboard OK (LV_EVENT_READY): read the text area, save to NVS, update the send button label, navigate back. On Cancel: navigate back without saving. Phase 5: Morse Code Engine Build morse.h with the full A–Z / 0–9 lookup table, a textToMorse() converter, and Paris-standard timing (unit_ms = 1200 / wpm). Phase 6: Non-Blocking LED Transmission State machine (IDLE / LED_ON / LED_OFF) driven by millis() in a morseUpdate() function called every loop — no delay(). LED on GPIO 17 (blue). Phase 7: Wire the Send Buttons Each button calls startMorse(getMessage(slot)) if not already transmitting. Disable all send buttons during TX; re-enable when the state machine reaches the end. Phase 8: Integration & Polish Stop button, WPM persistence, empty-slot guard, serial debug output, final touch calibration, end-to-end test checklist. --- Recommended order: Phase 1 → 2 → 7 (partial) → 5 → 6 → 7 (full) → 3 → 4 → 8 This was wild! Claude determined exactly how far along I was in the project, and also alerted me to the fact that the "touch read was stubbed out". Ugh. This means that the files I had uploaded to GitHub were my original GUI files (Episode 05 – HPR4532 - https://hackerpublicradio.org/eps/hpr4532/index.html ) and not the ones that I finally got working properly (Episode 07 – HPR4624 - https://hackerpublicradio.org/eps/hpr4624/index.html ). That was my own fault. Did I mention that I don't get Git? I REALLY need to learn to properly use Git! But, we have a plan, broken down by eight numbered phases. And they seem to address all the functionality I wanted with a few additional things I had not thought about. Interestingly, even though these phases are sequentially numbered, Claud recommended that we approach them in a bizarre order: Phase 1 → 2 → 7 (partial) → 5 → 6 → 7 (full) → 3 → 4 → 8 . Alright. Let's see what we can do. The first phase is to fix the touchscreen input. Claude took me through it step-by-step, asking as it needed to read specific project files. Finally, it wrote a new ui.ino code file to my speficied output directory for me to test. I copied it into the correct file location, said a quick prayer, compiled in Arduino IDE, and downloaded to the CYD. Well, that is... interesting. The display looked nothing like it was supposed to. There were vertical green bars with smaller dashed green vertical stripes in them. I will include a picture in the show notes so that you can see what it looked like and why it was so difficult to describe. I spent the next hour or so trying to explain what I was seeing to a chat bot. Claude recommended potential fixes which either did nothing or made the situation worse. I began questioning whether this was a good idea, how people actually gained efficiencies talking to a bot, and even several life choices. Then I had a thought. I prompted Claude: If I were to take a picture of the screen on the cheap yellow display and copy it into the output folder, would you be able to analyze it to better determine what is wrong and how to fix it? Shockingly, Claude answered in the affirmative, and told me to copy the picture to the output folder and let it know when to proceed. It analyzed the picture and more of the supporting files it had copied from my GitHub, asking each time if it could access that file. It determined that my original code was written for a flavor of LVGL version 8 and I was now using LVGL 9.5. It recommended changes, and then asked permission to make those changes, file by file. .h files & .c files, Finally, I just gave it permission to edit the files in the project folder without asking for permission for each file each time. Claude was still explaining each change, showing me exactly what would be changed, and asking for permission, so that I could review all of the changes. But now it was not asking additional permission to write to each of the impacted files. Next, Code compiled and downloaded. Different screen, but not right. Again, I took a picture and gave it to Claude to analyze. So, Claude paused and altered the code to generate a specific test pattern overtop of the GUI. The test pattern was supposed to cover the entire rectangular screen. But parts of the pattern were in a square on the screen and parts were not. Another photograph and analysis, told Claude that there were some rotation/screensize issues. We repeated this several times. Some resulted in improvement, and others did not. This is the point where I noticed something interesting. Not about Claude, specifically, or about the app. But I noticed something interesting about myself and about the process. Previously, when I was working through some of these challenges without Claud, I found myself becoming more and more stressed, frustrated, and angry, until I found a solution. Then another problem would repeat the cycle. Success in the end was great, but the emotional extremes during the process were not always pleasant. Now, I was effectively managing the project, and relaying information to the resource responsible for fixing the problems -- a very different experience. But I also ran into another issue. Claude became absolutely certain that the problem revolved around the device not accurately knowing where the 4 corners of the screen were. But in reality, the output of the test pattern was rotated 90 degrees from the actual screen. It took several iterations of me insisting that the problem had to do with screen orientation and not corner coordinates. It was interesting to experience the tool doubling down on an obvious mistake, but we finally resolved that. Again, while it was frustrating, it was much less stressful. We proceeded to Phase 2: Persistent Message Storage where we ensured that the button labels on the send screen were stored in the devices persistent storage, so that, when they are edited to contain the message they should send, that information would survive a reboot. Next, we combined elements of Phase 5: Morse Code Engine , Phase 6: Non-Blocking LED Transmission , and Phase 7: Wire the Send Buttons together. Building the morse code engine was an area I had been thinking about for a while. I already had working parts of something similar in the Arduino practice oscillator I have referenced a few times in this series. The code for the practice oscillator may be found on my GitHub, but it was all based on original code from jmharvey1, with my only contribution being making pin assignments variables so that the code could easily be ported to different devices. So, I was happy that we were building the morse code engine directly. The code for it may be found in morse.h, which uses a constant character lookup table to define each character. Without any specific direction from me, Claude used the PARIS timing methods I have already described within Episode 6 of this series. It defines timing for DOT, DASH, LETTER_GAP, and WORD_GAP, and all are based on a simple calculation of 1200 ms / the number of words per minute (WPM) we wish to transmit. Along the way, we discovered that, if we tried to use the delay() function, it would crash the program due to a conflict with the LVGL timer used for touchscreen inputs. Claude altered all the delays accordingly. Then, Phase 3: Config Screen — Slot Selection & Speed allowed us to configure the WPM we wished to use in addition to selecting a specific Send button to reconfigure. This forced us to work on Phase 4: Keyboard Screen — Capture and Save Text which is used to type the entries for each Send button. At this point, I also decided that we would want to also use the Keyboard Screen to send ad hoc morse as we typed it. During this phase we discovered several bugs which seemed to cause random freezes. Careful troubleshooting with messages output to the Arduino IDE's serial console helped us narrow down the causes and remedy them. Finally all the tests worked and I am able to merrily pre-configure macro buttons with custom messages and use the CYD to send the morse code for those messages to the on-board LED at whichever rate I specify. I have noticed in my presentation of this narrative that I repeatedly slip into the first person plural terms "we" and "us" instead of the first person singular terms "I" and "me". I have unconsciously personified Claud and recognized it as an integral part of my (formerly one person) development team. I finally configured Claude to connect to my GitHub repo and upload all the files and documentation. We additionally created a CYD-Narrative.md file which describes in more detail all the work which was done on the project. I still do not 100% get git, but we are successfully using it. You can find all these files in my GitHub repo ( https://github.com/jttrey3/CYD_MorseSender ) where they are shared under a GPL 3.0 license. There are still several additional steps I plan to complete in the next few months. 1. I will be integrating an opto-isolated relay which will allow me to plug the device into the straight key input on any amateur radio. This will require a battery power source, charge controller, and more hardware. I... make that "We" (Claude & I) will be modifying the code to support an audio side tone through an attached speaker when sending code We will add an output selection switch to the config page to choose any combination of speaker, relay, or LED as output. We will develop a downloadable firmware which I hope to share with the Cheap Yellow Display community. If you can think of any additional features you would like to see integrated, please drop me an email using the address in my HPR profile. I may also work with a friend to attempt to 3d print a case for the entire contraption, and I will be sure to record additional episodes sharing the process. I have learned so much throughout this project, about the CYD, ESP32, GUIs, Claude Code, GitHub, and most of all, about myself. Does using AI to develop this code make me a fraud? It still feels like it in some ways. Does it make me more productive? ABSOLUTELY! I made consistent forward progress when I only had 30-60 minutes each day to work on it, and everything discussed in this episode was completed in less than a week. If I had been able to work on it for a few hours uninterrupted, it may have only taken me 3-5 hours. Does it empower and inspire me to do more projects like this? 100% I feel like I had support working with me the whole way. I was less stressed overall, and it had less of an impact on the amount of and quality of time I spent with my family. I will be wrapping up this series soon, without any more 6 month gaps, I hope. Until next time... Provide feedback on this episode.

In 2025, the FDA approved the antibody-drug conjugate (ADC) enfortumab vedotin combined with pembrolizumab for patients with cisplatin-ineligible muscle-invasive bladder cancer, unlocking a new perioperative treatment option. To administer this ADC-based therapy alongside surgical intervention, multidisciplinary teams must prioritize collaborative workflows at all points of the treatment journey. In this episode, CANCER BUZZ speaks with Manojkumar Bupathi, MD, President of Rocky Mountain Cancer Centers, about how ADCs are reshaping the care model toward earlier, structured collaboration between urology and medical oncology. Guests: Manojkumar Bupathi, MD President Rocky Mountain Cancer Centers Co-Chair, GU Executive Committee Sarah Cannon Research Institute Denver, CO "The challenge wasn't learning the drug itself. The challenge was how you integrate the regimen into your treatment paradigm." —Manojkumar Bupathi, MD "There's always this relationship that happens from the beginning and is maintained throughout the entire process." —Manojkumar Bupathi, MD Resources: ACCC Bladder Cancer Resources ACCC Antibody-Drug Conjugate Resources  

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into an array of groundbreaking advancements and strategic movements reshaping the landscape of healthcare and medicine. Recent strides in Alzheimer's research have highlighted Biogen's promising Phase 2 clinical trial results for diranersen, an antisense oligonucleotide targeting the tau protein. Unlike traditional amyloid-targeting therapies, this approach offers a novel mechanism that could diversify treatment options for Alzheimer's patients. By addressing tau pathology, a critical feature of Alzheimer's disease, Biogen's findings may influence research trajectories and potentially lead to improved patient outcomes. In tandem with this, Biogen and Eisai have received FDA approval for a subcutaneous formulation of Leqembi (lecanemab), targeting amyloid-beta plaques. This new delivery method is poised to enhance patient compliance and accessibility, marking significant progress in broadening Alzheimer's treatment modalities. In oncology, AstraZeneca has entered into a substantial $1.5 billion licensing agreement with Dizal Pharmaceutical for lung cancer therapies. This strategic partnership emphasizes the importance of collaborative efforts in advancing cancer treatment and highlights the role of targeted therapies in addressing unmet medical needs. Additionally, Merck KGaA's Erbitux has secured European Commission approval for first-line treatment of BRAF V600E-mutant metastatic colorectal cancer. By focusing on specific genetic mutations, this approval illustrates the shift towards precision medicine, where treatments are tailored based on individual genetic profiles. The industry is also embracing advanced technologies such as artificial intelligence (AI) to enhance drug discovery processes. Chai Discovery's partnership with Novartis exemplifies this trend, as they focus on AI-driven therapeutic antibody discovery. Meanwhile, Ardigen and Veraxa Biotech's collaboration in optimizing T-cell engager and ADC drug discovery demonstrates AI's growing role in reducing timeframes and costs associated with bringing new therapies to market. Regulatory updates from the FDA seek to streamline registration rules to alleviate manufacturing burdens for biopharma companies, reflecting ongoing efforts to improve operational efficiencies in drug production. Additionally, new guidance on psychedelics indicates a regulatory openness that could stimulate innovation within neurological therapeutics. In other news, HUYABIO's Phase 3 trial results have shown promise for advanced skin cancer patients through a combination therapy involving Bristol Myers Squibb's Opdivo. This success underscores the potential of combination therapies to enhance treatment efficacy. Meanwhile, cell therapy is experiencing a transformative shift with Cellares' advancements in automating manufacturing processes. These innovations promise broader access to life-saving cell therapies by accelerating production timelines and reducing costs. Turning to business developments, Spero Therapeutics' $1.1 billion deal with Innovent Biologics marks a strategic pivot towards immune modulation therapies, highlighting the growing interest in autoimmune diseases. Concurrently, Avere Therapeutics' public listing via a reverse merger with NextCure and acquisition of an IL-23 drug signifies ongoing consolidation within the sector. On the regulatory front, Beckman Coulter's expansion of its Alzheimer's diagnostic portfolio through a CE mark for its p-tau217 assay enhances diagnostic capabilities crucial for early detection and management amid an aging global population. As we look globally, cities like Basel and Beijing are emerging as biotech hubs, attracting top talent and investments while fostering innovation. Amid these shifts, industry professionals are encouraged to adapt to evolving technological landscapes, particularly with AI poised to enhance decision-making processes and streamline clinical workflows. These developments illustrate a dynamic phase for pharma and biotech sectors where scientific breakthroughs are closely intertwined with strategic business decisions and regulatory advancements. As we continue to navigate these changes, the potential for delivering more effective treatments across various therapeutic areas is immense. Stay tuned as we bring you more insights into how these innovations are shaping the future of healthcare globally. Thank you for joining us at Pharma Daily; until next time.Support the show

As political parties prepare for the 2027 general election, unity may prove just as important as popularity.But a fresh Appeal Court ruling involving the African Democratic Congress (ADC) has raised questions about the party's internal leadership and what lies ahead.Today on Nigeria Daily, we ask: What does the Appeal Court ruling really mean for the ADC?I am Luqman Awwal Agono. My guests are Bolaji Abdullahi, National Publicity Secretary of the African Democratic Congress (ADC); Paul Ibe, spokesperson to former Vice President Atiku Abubakar; and Mr. David West, political analyst.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative updates and strategic shifts within the industry, reflecting both remarkable progress and inherent challenges. Sanofi's recent achievement marks a significant milestone in oncology with the FDA approval of Sarclisa Escena (isatuximab) as the first on-body injector for multiple myeloma treatment. This monoclonal antibody, targeting CD38, offers a novel subcutaneous delivery method, simplifying administration and potentially enhancing patient compliance by reducing the need for frequent clinic visits. This aligns with the industry's ongoing shift towards patient-friendly drug delivery systems, emphasizing convenience without compromising efficacy. In another promising development, GSK and Hansoh Pharmaceutical have reported positive results from their Phase 3 trial evaluating risvutatug rezetecan for small cell lung cancer. This antibody-drug conjugate, targeting B7-H3, has shown potential when combined with chemotherapy to extend patient survival. Given the aggressive nature of small cell lung cancer and limited treatment options, these findings underscore the potential of targeted therapies to improve clinical outcomes significantly. Forte Biosciences' FB102 also takes a spotlight in clinical advancements. In its Phase 1b trial for vitiligo, FB102 demonstrated a 45.8% placebo-adjusted benefit. This monoclonal antibody works by modulating immune responses through the IL-15 pathway via CD122, offering new hope for patients with this challenging autoimmune condition. On the regulatory front, ARPA-H's commitment of up to $160 million towards developing personalized genetic medicines for rare diseases is noteworthy. This investment is set to accelerate innovations in gene therapy and personalized medicine platforms. Such advancements promise to revolutionize pediatric care and extend beyond by tailoring treatments to individual genetic profiles, enhancing efficacy while minimizing adverse effects. Strategic collaborations continue to reshape the industry landscape. Rani Therapeutics' partnership with PegBio aims at advancing oral delivery systems for obesity and metabolic diseases. Similarly, Simcere Pharmaceutical's collaboration with Schrödinger leverages AI-driven drug discovery efforts. These alliances highlight an increased reliance on computational platforms to streamline therapeutic development processes. From a financial perspective, Mesoblast Limited reports substantial revenue from its cell therapy product Ryoncil, signaling strong commercial viability for cell-based treatments targeting rare diseases. Additionally, Cue Biopharma's successful $50 million fundraising underscores investor confidence in advancing therapies for immunological disorders. However, not all news is positive. Roche has decided to halt two programs targeting Huntington's disease due to inadequate efficacy and safety concerns. This decision reflects the complexities involved in developing effective treatments for neurological disorders—a field fraught with scientific challenges yet rich with potential rewards. In market dynamics, McKinsey's report advocates for a structural redesign of biopharmaceutical R&D to fully leverage AI's capabilities. This recommendation resonates with current industry trends focusing on strategic innovation to maximize efficiency and discovery potential. The FDA's third rejection of Hengrui Pharma and Elevar Therapeutics' combination therapy for liver cancer underscores the rigorous scrutiny such treatments face despite their promise in addressing complex cancers. In contrast, BioNTech's preparation to launch its HER2 antibody-drug conjugate (ADC) signifies its strategic pivot back towards oncology after mRNA vaccine successes. Bayer's decision to sell a minority stake in its contraceptives business demonstrates how companies are strategically realigning portfolios to focus on core areas while securing funding for innovation. This move reflects broader trends within pharma as companies navigate financial landscapes to support long-term research goals. Amid these developments, regulatory environments continue evolving. NICE's stance against future Lumakras reimbursement in the UK highlights ongoing challenges in balancing cost-effectiveness with access to innovative therapies. Meanwhile, ARPA-H's significant funding allocation signals robust governmental support for advancing precision medicine within genetic therapies. In conclusion, today's updates reveal an industry characterized by a relentless pursuit of innovation amidst complex regulatory landscapes. As companies navigate these dynamics through strategic collaborations and scientific breakthroughs, their efforts hold promise for enhancing patient care across diverse therapeutic areas globally. Stay tuned as we continue to track these exciting developments shaping the future of pharmaceuticals and biotechnology. Thank you for tuning into Pharma Daily—your go-to source for up-to-date insights from the world of pharmaceuticals and biotechnology.Support the show

On this week's episode, Sam Fazeli, Josh Schimmer, Eric Schmidt, Paul Matteis, and special guest STAT's Matt Herper open on the market, noting that despite a wobbly day for biotech, the XBI holds strong gains year-to-date. The conversation turns to FDA transparency, where the co-hosts flag that CRLs haven't been released since April and that the agency may be walking back that practice. The co-hosts debate whether the FDA is swinging too far toward leniency after Agios' mitapivat won priority review in sickle cell disease despite missing its primary endpoint last year. On AI in drug discovery, Matt Herper recaps an interview with Anthropic's CEO about a new research tool, noting that it's plausible the tool helps industry pick better targets and lower the failure rate. In M&A, Vertex's largest-ever deal takes Crinetics for $10 billion net of cash, staking a claim in the specialty rare endocrine space, while Novartis expands its ADC portfolio with Myricx for $1.1 billion upfront plus $400 million in milestones — the second European ADC deal in recent months. On data, AstraZeneca and Ionis' eplontersen trial in ATTR-CM missed its endpoint, showing no benefit or biomarker signal on top of background tafamidis; the group then discusses the readthroughs for BridgeBio, Alnylam, and Pfizer's ATTR therapies. This episode aired on July 10, 2026.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The first quarter of 2026 has brought a wave of significant changes and advancements in the industry, marked by crucial regulatory updates, strategic acquisitions, and shifts in the competitive landscape. A pressing issue for many companies is the looming patent cliff for several branded biologics. This situation presents both challenges and opportunities for biosimilars in the U.S. market. The introduction of biosimilars for major products like AbbVie's Humira, Johnson & Johnson's Stelara, and Regeneron/Bayer's Eylea is shifting the narrative from slow adoption to a more competitive biosimilar market landscape. Vertex Pharmaceuticals has achieved a milestone with the FDA expanding the label for its gene therapy Casgevy, now approved for treating children as young as two with sickle cell disease or transfusion-dependent beta thalassemia. This expansion emphasizes the potential of gene therapies to revolutionize treatment options for younger patients suffering from these conditions. In a pivotal development, Novartis announced a significant acquisition of UK biotech Myricx. With an upfront payment of $1.1 billion and potential total value up to $1.5 billion, this acquisition is set to enhance Novartis' antibody-drug conjugate (ADC) pipeline by incorporating Myricx's novel payload technology and NMT inhibitor payloads. This move reflects Novartis' focus on precision oncology by improving ADC efficacy through targeting critical enzymatic pathways involved in tumorigenesis. Amgen faced a setback with a voluntary recall of approximately one million bottles of its heart medication Corlanor due to potential contamination, highlighting the critical importance of maintaining rigorous manufacturing quality control to ensure drug safety. The regulatory landscape continues to evolve, illustrated by Robert F. Kennedy Jr.'s Department of Health and Human Services revoking lingering COVID-19 emergency authorizations. This signals a transition towards post-pandemic normalcy and an evolving focus on pandemic preparedness frameworks. Sanofi's Genzyme unit in Ireland faced criticism after an FDA inspection linked to Altuviiio resulted in a Form 483 notice. This incident underscores ongoing challenges in maintaining compliance with stringent regulatory standards and emphasizes the importance of robust quality assurance mechanisms. Lonza is expanding its capacity for producing ADCs and enhancing its partnership with a large U.S. drugmaker, aligning with industry trends toward outsourcing complex biologics manufacturing amid growing demand for ADCs. Genentech is undergoing restructuring, resulting in 103 layoffs as part of a strategic rethink of its early development group. Despite these changes, Genentech entered a $490 million collaboration focused on breast cancer, demonstrating its commitment to innovation amid organizational shifts. AstraZeneca continued its collaborative efforts by signing a $1.7 billion kidney drug discovery pact with Chinese biotech CSPC Pharmaceutical. This partnership emphasizes AstraZeneca's strategy to leverage global collaborations to accelerate drug discovery and development efforts. Scribe Therapeutics filed for an Initial Public Offering (IPO) to advance its CRISPR-based gene editing technologies targeting cardiovascular diseases at a genetic level, highlighting an ongoing shift toward personalized medicine. Celea Therapeutics raised $180 million in venture funding to advance Deupirfenidone into late-stage clinical trials for Idiopathic Pulmonary Fibrosis (IPF), signaling confidence in its therapeutic potential amid ongoing investment trends targeting rare diseases. The Medicines and Healthcare products Regulatory Agency expanded approval for Novo Nordisk's Wegovy for Metabolic-Associated Steatohepatitis with moderate-to-advanced liver fibrosis. This expansion represents significant progress given MASH's rising prevalence and progression risks. BridgeBio's ATTRibute-CM study yielded promising results with Acoramidis offering kidney-protective benefits in transthyretin amyloidosis cardiomyopathy patients—a potential new approach managing this rare disease. Revolution Medicines reported encouraging data for its KRAS inhibitor Zoldonrasib in combination therapies targeting metastatic pancreatic ductal adenocarcinoma—offering new strategies against aggressive cancer types. Brii Bio's phase 2b trial results show promise for a combination therapy aimed at achieving a functional cure for chronic Hepatitis B Virus infection—offering hope for millions affected by this condition. Robust fundraising activities continue within biotech sectors as Monash University and Atisama Therapeutics secure funding from MRFF grants developing therapies targeting chronic lung diseases. Overall, these developments highlight dynamic transformations reshaping therapeutic landscapes through precision medicine approaches leveraging cutting-edge technologies promising improved patient care across various domains within pharmaceutical industries globally.Support the show

Editor-in-Chief of the Archives of Disease in Childhood, Dr Nick Brown, and Senior Editor of ADC, Dr Rachel Agbeko, bring you the monthly Atoms - the highlights of the July 2026 issue. Read it on the Archives of Disease in Childhood website: https://adc.bmj.com/content/111/7/i  Please listen to our regular podcasts and subscribe in Apple Podcasts, Google Podcasts, Stitcher and Spotify to get episodes automatically downloaded to your phone and computer. And if you enjoy the podcast, please leave us a review at https://podcasts.apple.com/gb/podcast/adc-podcast/id333278832 

As political parties prepare for the 2027 general election, unity may prove just as important as popularity.But a fresh Appeal Court ruling involving the African Democratic Congress (ADC) has raised questions about the party's internal leadership and what lies ahead.Today on Nigeria Daily, we ask: What does the Appeal Court ruling really mean for the ADC?I am Luqman Awwal Agono. My guests are Bolaji Abdullahi, National Publicity Secretary of the African Democratic Congress (ADC); Paul Ibe, spokesperson to former Vice President Atiku Abubakar; and Mr. David West, political analyst.

In today's episode, we spoke with David O'Malley, MD. Dr O'Malley is a professor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center–James in Columbus, Ohio. In our exclusive interview, Dr O'Malley discussed his approach to treatment selection and sequencing in platinum-resistant ovarian cancer, a disease setting he described as representing the highest unmet need in the field. He emphasized the central role of clinical trial enrollment and biomarker-driven decision-making, alongside practical patient-centered considerations, such as infusion schedule and quality of life.He highlighted the growing importance of antibody-drug conjugates (ADCs) in this setting, noting that folate receptor alpha and HER2 are the two biomarkers most relevant to current practice. Dr O'Malley outlined how National Comprehensive Cancer Network guidelines support treatment across a broader range of expression levels than initial approvals reflected, citing emerging data suggesting activity even at lower expression thresholds. He also addressed payload sequencing, explaining that outside of a clinical trial, he currently uses topoisomerase I–based ADCs and antimicrotubule-based ADCs each one time only, and remains open to targeting the same antigen again if the payload differs.The discussion also touched on combination strategies, resistance biology, and the evolving role of immunotherapy following the survival benefit observed with pembrolizumab (Keytruda) in the phase 3 KEYNOTE-B96 trial (NCT05116189). Dr O'Malley expressed enthusiasm for next-generation payloads, dual-target approaches, and the potential for bispecific antibodies and novel DNA damage response–targeting agents to define the post-ADC treatment landscape.Finally, Dr O'Malley underscored the need for more tumor biopsies to better characterize resistance mechanisms and called for expanded pharmaceutical investment in retreatment and cross-resistance studies to guide future sequencing decisions.

The opposition says it is determined to unseat the ruling APC in 2027. But can it achieve that if one of the platforms expected to play a major role is caught in a legal battle?A recent court ruling has thrown the future of the NDC into uncertainty, prompting questions about what happens if the party eventually loses its registration. Would that derail Peter Obi's political ambitions? Would it affect ongoing talks among opposition figures? Or is this simply another legal hurdle that can be overcome?In this episode of Nigeria Daily, we examine what the court's decision really means, what the opposition is saying, and whether Nigeria's political landscape could change before the next general election.

The Tim Conway Jr. Show Hour 2 (6.25) This hour goes from hope to havoc. We kick off with a real breast cancer breakthrough — the FDA just greenlit Trodelvy as a first-line treatment for the hardest-to-treat triple-negative breast cancer, the first ADC approved across PD-L1 status, and it's already proving more durable than chemo. Then sports get ugly: the WNBA suspended Phoenix's Alyssa Thomas and slapped her with a flagrant 2 for driving her fist into Caitlin Clark's throat — a hit refs somehow missed live. Next, the House Whisperer himself, Dean Sharp, breaks down home electrical do's and don'ts (electricity isn't magic, it's water in a pipe) and the man-stuff guide to buying power tools. And we close on the stench story gripping LA: 85 million pounds of spoiled meat, seafood, and bread rotting inside a burned-out Boyle Heights warehouse, as crews race to haul it out before it becomes a full-blown biohazard. Breakthroughs, cheap shots, and a biohazard. Hit play. breakthrough, game-changer, greenlit, FDA-approved, cheap shot, flagrant, dropped the hammer, no-call, caught on camera, ugly, stench, biohazard, rotting, race against time, hauled out, do's and don'ts, man stuff, must-know, dangerous, exposed, accountability, fallout, sidelined, suspended, slammed, viral, jaw-dropping, hope vs. havoc, the truth about, what you need to know. See omnystudio.com/listener for privacy information.

Keith, Terry, and Jill discussed recent activities. Keith shared details about attending a local festival in Livingston, Illinois featuring a pink elephant statue, where they saw a beauty pageant and discussed potentially involving Andrea in an upcoming Miss UFO pageant. The conversation also touched on family activities, including Jill’s camping trip with four grandchildren and Keith’s church fishing outing. Keith shared updates about his weekend activities, including Robin buying dirt boxes with treasures for three children and plans to register for a Miss UFO event. The group discussed their new Amazon storefront, which is still being developed and populated with relevant products. Support our podcast by shopping at our Amazon marketplace page:see what selling fast on Amazon! News of the Week Terry then shared a news story about an overturned semi-truck in Texas containing an estimated 2 million bees from Queen Bee Supply Company, which required local residents to stay indoors while the bees were rounded up and transported to a honey farm. Jill shared about Jonathan, a 194-year-old turtle living on Saint Helena island, while Terry presented stories about German man Tommy Schmidt’s record-breaking 65,000 Lego brick bratwurst sculpture and an Oklahoma family’s surprise when their dog brought an armadillo into their home. Keith then described a story about a month-old pony named Mile who moved into an apartment in Croatia after being rejected by his mother, requiring round-the-clock care and eventually gaining weight and appearing cheerful. Terry shared two news items: a truck fire in Tennessee caused an impromptu fireworks display on Interstate 75 near Chattanooga, and a police department in Washington discovered a bird nest with four eggs in a motorcycle’s engine compartment, which they named “Traffic Birdie.” Jill's Weird Words The group then played a game of “weird words,” where Jill presented definitions and participants guessed meanings, covering terms like Freudian, manifold, woodshed, pan dowdy, coloratura, prolix, ADC (adze), and recondite. As the group discussed word meanings and etymologies, Jill explained terms like “firth” as a narrow sea inlet and “toodle” meaning to travel leisurely. Terry's Top 10 List Terry shared a humorous top ten list about reasons someone might need a CAT scan, which included jokes about cats acting as radiologists and other playful scenarios. Anchor Topic The segment of the show where we discuss blindness related topics. On the schedule is low vision, but we decide to return to living skills.Keith leads the focus on daily self-care activities like getting dressed and bathing while emphasizing the importance of independence. The group discussed strategies for blind individuals to identify bathroom products, including using rubber bands to mark bottles, organizing them on different shelves, and reading labels before showering. Keith and Terry shared personal experiences with accessibility challenges in bathrooms, including issues with children moving products and the benefits of pump bottles secured to shower walls. Email and Final Thoughts Keith presents an email from a listener in Florida who runs an alligator farm. He follows it by a touching story about a woman, a mother of three, who practice the principle of “pay it forward,” when she helped out another young mother years later. There are also two voicemails that are shared. The first from a young farmboy with an overturned wagon. The next one contains some food for thought that ponders the issue of evil. As usual, we wrap it all up with our final thoughts. The final word from our AI companion The meeting was a recording session for a comedy show where Keith, Jill, and Terry shared various content including email submissions, voicemails, and their own jokes. Keith read several email submissions including stories about a rattlesnake farm visit and an anonymous act of kindness at a mechanic’s shop. The team discussed a news story about singer Olivia Rodrigo’s comments about concertgoers wearing adult diapers for prime seating positions, and shared philosophical content about evil and its existence. The session concluded with the team taking turns sharing final thoughts and jokes before signing off. Show notes written by AI, edited as needed by Keith. Sponsored by: Retro Radio Podcast. Bringing you family-friendly entertainment through classic, old-time radio. Episodes are posted daily. Keith and his Retrobots share everything in his collection from the days of vintage radio. Adventure, comedy, detective, westerns, and lots in between. If you don't hear your favorite show, just ask Visit the web page today, https://retro-otr.com

Doing stuff is easy, not doing stuff is hard, particularly if you've been doing it for a year. This isn't just about smoking, drinking, and wild banjo playing on the porch at midnight, though we talk about it on the podcast (https://adc.bmj.com/content/111/5/457.2), but also echoed in an upcoming Editorial (https://adc.bmj.com/content/early/2026/04/03/archdischild-2026-330309). If reality were alterable by waving your hand, do you think you might do it? If you're intrigued, the work on X-rays for PICC-tips might enthrall you (https://adc.bmj.com/content/111/5/457.1) or just wave at people. See what happens. (Note, the ADC is not responsible for any adverse events if you do this in London rather than the North!). This podcast is written and presented by Prof Bob Phillips (Hull-York Medical School, UK), Archimedes section editor of Archives of Disease in Childhood. He brings you the monthly episode about evidence-based medicine for paediatricians. We would love for you to be involved in Archi [https://adc.bmj.com/pages/authors#archimedes]. Just ask the questions that your patients are offering you - and tell us how you're finding the podcast offerings. Please listen to our regular podcasts and subscribe in your preferred platform to get episodes automatically downloaded to your phone and computer. And if you enjoy the ADC Podcast, please leave us a review at https://podcasts.apple.com/gb/podcast/adc-podcast/id333278832.

 The Ekiti State governorship election has been concluded, with incumbent governor Biodun Abayomi Oyebanji of the APC securing another four-year mandate after defeating candidates of the PDP, ADC, and other political parties.But even as celebrations begin, questions remain over whether the opposition will accept the outcome and whether allegations of vote-buying and electoral irregularities could end up in court. Join us in this episode of Nigeria Daily as we examine the reactions from the major political parties and what the Ekiti election could mean for the 2027 general elections. 

Timestamps0:00 Intro 1:06 Welcome Aux 2:31 LCK recap from First Stand 9:16 HLE in spring 20:28 HLE player by player 41:48 The ideal ADC style 49:47 T1 56:12 Peyz on T1 1:06:50 Aux MSI predictions 1:13:37 Welcome Emily -- TES 1:34:14 WE what did they do 1:44:00 Knight and BLG 1:57:50 Emily MSI predictions

For years, political defections have remained a recurring feature of Nigeria's democratic journey, with politicians frequently moving from one party to another after winning elections.Now, the National Democratic Congress, NDC, has introduced a policy requiring all candidates seeking elective offices on its platform to sign anti-defection affidavits and indemnity forms, committing themselves to vacate their seats if they leave the party after winning elections.The move has sparked fresh debate about political loyalty, party discipline and whether elected officials should be allowed to retain their mandates after defecting from the parties on which they were elected.Join us in this episode of Nigeria Daily as we examine why the NDC introduced the policy, what it hopes to achieve, and whether anti-defection affidavits can help strengthen Nigeria's democracy ahead of the 2027 elections.

For years, political parties have served as the platforms through which politicians seek power, build alliances, and contest elections in Nigeria.Now, a Federal High Court ruling directing INEC to deregister the African Democratic Congress (ADC) and four other political parties has sparked fresh debate about the future of opposition politics and democratic competition ahead of the 2027 general elections.Join us in this episode of Nigeria Daily as we examine what the ruling means for the ADC, the politicians aligned with the party, including former Vice President Atiku Abubakar, and the future of Nigeria's political landscape.

Tanya Dorff joins Tom and Brian to discuss her ASCO 2026 data on a novel dual targeting ADC in prostate cancer. The broader scope of ADC development in prostate cancer is discussed with a focus on cytopenia toxicity and future direcctions.

In this episode of Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Neil M. Iyengar, MD, an associate professor and co-director of Breast Medical Oncology in the Department of Hematology and Medical Oncology at the Emory University School of Medicine, as well as the director of Survivorship Services at the Winship Cancer Institute of Emory University in Atlanta, Georgia.Their conversation focused on the rapidly evolving treatment paradigm for triple-negative breast cancer (TNBC), the integration of metabolic health strategies, the clinical emergence of antibody-drug conjugates (ADCs) in the frontline metastatic setting, and the management of treatment-related toxicities.Drs Park and Iyengar examined data from the phase 3 TROPION-Breast02 trial (NCT05374512), which evaluated first-line datopotamab deruxtecan-dlnk (Dato-DXd; Datroway) in patients with PD-L1-negative metastatic TNBC. The trial demonstrated improvements in both progression-free survival and overall survival (OS) with Dato-DXd compared with standard chemotherapy. Notably, the experts also highlighted a remarkable ORR with Dato-DXd, showing that the ADC may be a robust treatment option for symptomatic patients or those experiencing rapid progression.They also discussed individualizing treatment between Dato-DXd and sacituzumab govitecan-hziy (Trodelvy) based on biomarker status, dosing schedules, and distinct toxicity profiles. Furthermore, the experts emphasized the importance of proactive management of unique ADC-associated toxicities. For Dato-DXd, they recommended prophylactic dexamethasone mouthwash and lubricating eye drops to mitigate mucositis and corneal surface events. For sacituzumab govitecan, they noted the necessity of growth factor support for neutropenia and loperamide for diarrhea.Regarding early-stage disease, they reaffirmed the phase 3 KEYNOTE-522 trial (NCT03036488) regimen of pembrolizumab (Keytruda) plus chemotherapy as the standard of care, with adjuvant escalation using capecitabine or PARP inhibitors for patients with residual disease.Drs Park and Iyengar concluded by spotlighting metabolic health interventions for patients with breast cancer. Although GLP-1 receptor agonists show promise in breast cancer survivors, Dr Iyengar cautioned against their initiation during active neoadjuvant immunotherapy due to their potential effects on pathologic complete response rates. He advocated for lifestyle interventions, including resistance training and a plant-forward, high-protein diet, to maintain lean muscle mass and improve OS outcomes.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/the-evolving-role-of-antibody-drug-conjugates-in-metastatic-triple-negative-breast-cancer-10800SummaryThis CME/CE-certified podcast will provide multidisciplinary clinicians with an evidence-based update on the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline treatment of metastatic triple-negative breast cancer. A medical and an ocular oncology specialist review the latest efficacy and safety data from pivotal clinical trials evaluating ADCs, their integration into contemporary treatment algorithms, and guideline recommendations based on PD-L1 status, BRCA mutation status, and immunotherapy eligibility. Learners will explore key factors influencing treatment selection, compare the benefits and limitations of more established therapeutic options, and examine practical strategies for preventing, recognizing, and managing ADC-associated toxicities. Special emphasis will be placed on multidisciplinary approaches to the management of ocular adverse events and other clinically significant toxicities to optimize patient outcomes and support safe implementation of these therapies in clinical practice.Learning ObjectivesEvaluate the current and emerging clinical evidence surrounding the use of trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugates (ADCs) in the first-line treatment of metastatic triple-negative breast cancer (TNBC)Integrate TROP2-directed ADCs into frontline treatment regimens for metastatic TNBC based on the latest clinical evidence, guidelines, and patient- and tumor-specific factorsApply multidisciplinary and patient-centric strategies for the prevention, recognition, and management of toxicities associated with the use of TROP2-directed ADCs in patients with metastatic TNBCThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.50 contact hours (which includes 0.50 hours of pharmacology). For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Faculty and Moderator Aditya Bardia, MDProgram Director, Breast Medical Oncology, UCLAProfessor of Medicine, UCLALos Angeles, CADr. Bardia has disclosed the following financial relationships:Consultant: Alyssum, AstraZeneca/Daiichi, BMS, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, VyomeAdvisor/Advisory Board: Alyssum, AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, VyomeContracted Research: AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, PfizerStock options: Vyome (immuno-inflammatory and rare diseases)All of his consultant, advisor/advisory board, and contracted research disclosures are related to cancer.Maura Di Nicola, MDAssistant Professor of OphthalmologyBascom Palmer Eye InstituteMedical Director of Imaging and EchographyBascom Palmer Eye InstituteMiami, FLDr. Di Nicola has disclosed the following financial relationships:Consultant: AbbVie (ophthalmology), SpringWorks Therapeutics (oncology)Advisor/Advisory Board: AbbVie (ophthalmology)Research Grant: Castle Biosciences (ocular oncology)Please review additional planner disclosures here.Disclosure of Commercial SupportThis educational activity is supported by a medical education grant from AstraZeneca Pharmaceuticals and a medical education grant from Daiichi Sankyo, Inc.Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

The proposal for a single six-year presidential term in Nigeria is once again dominating national conversations, sparking heated debate across political circles, governance experts, and social media platforms.At the heart of the discussion is a major question: Should Nigeria consider a six-year single term presidency as part of constitutional reform, or is it a dangerous shift that could weaken democratic accountability?The idea, which has resurfaced amid ongoing Nigeria constitutional amendment debates, touches on key issues such as electoral reform in Nigeria, presidential tenure limits, governance stability, and democratic accountability in Africa's largest democracy.Supporters say a single-term presidency in Nigeria could reduce the pressure of re-election politics, lower election costs, and allow leaders to focus fully on governance. Critics, however, warn it could reduce voter power, weaken checks and balances, and reshape Nigeria's democratic structure in ways that may not serve public interest.And so today on Nigeria Daily, we ask the big question trending across Nigerian politics, 2026 political news, constitutional reform Nigeria, and election reform discussions:

In this episode of the Mic On Podcast, Seun Okinbaloye sits with Solomon Dalung, former Minister of Youth and Sports Development and legal practitioner, who shares his views on coalition politics, governance, and the 2027 elections.Dalung discusses the challenges facing the ADC coalition, criticizes recent political realignments, and argues that growing insecurity and public dissatisfaction have weakened confidence in the current administration. He also reflects on his role in the formation of the APC, expressing disappointment with the party's performance in government.Looking ahead to 2027, Dalung urges Nigerians to prioritize competence over party loyalty and remain actively engaged in the electoral process, describing the next election as a defining moment for the country's future.Guest:Solomon Dalung(Former Minister of Youth and Sports Development / Legal Practitioner)

Toxicities related to antibody-drug conjugates (ADCs) can significantly impact quality of life for patients with locally advanced or metastatic bladder cancer, but data-driven programs can help multidisciplinary teams manage some of the most challenging adverse events. In this episode, CANCER BUZZ speaks with Cindy Y. Jiang, MD, assistant professor at MD Anderson Cancer Center, about how her institution conducted and implemented research to aid management of rashes and peripheral neuropathy associated with the ADC enfortumab vedotin combined with pembrolizumab. Guest:  Cindy Y. Jiang, MD Assistant Professor Department of GU Medical Oncology MD Anderson Cancer Center Houston, TX "It's important to assemble this team before you start on any sort of journey, because as oncologists, we're definitely not experts in skin rashes or neurological issues, and so you really need to rely heavily on those collaborators." — Cindy Y. Jiang, MD Resources: Bladder Cancer Antibody-Drug Conjugates

This episode of the PeerDirect Medical News Podcast examines the rapidly expanding Ebola outbreak in Congo and concerns over weakening global public health infrastructure, reviews new Phase III obesity data showing substantial weight loss with Lilly's triple-agonist retatrutide, and highlights promising ASCO 2026 lung cancer data for a TROP2-directed ADC combined with pembrolizumab in frontline NSCLC.

This episode featured @nigeriasbest and @phoenix_agenda They discussed:2027 General Election Primaries with a focus on ADC and NDC

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll explore a landscape teeming with strategic partnerships, groundbreaking clinical trial results, regulatory shifts, and innovative therapeutic approaches that are redefining patient care and drug development. Pfizer's monumental $10 billion collaboration with Innovent Biologics stands out as a testament to the shifting dynamics of the oncology sector. This partnership aims to develop 12 antibody-drug conjugate (ADC) and multispecific antibody programs, spotlighting these therapies' growing significance in oncology. The precision of antibodies in delivering cytotoxic agents directly to cancer cells offers a new frontier in minimizing collateral damage to healthy tissues—a crucial advancement in cancer treatment. The deal not only highlights Pfizer's commitment to expanding its oncology pipeline but also underscores the strategic importance of leveraging China's accelerated drug development ecosystem. In regulatory news, AstraZeneca's Imfinzi has garnered FDA approval for BCG-naive high-risk non-muscle-invasive bladder cancer. This milestone for PD-L1 inhibitors reflects the evolving landscape of immunotherapy. By harnessing monoclonal antibodies in combination therapies, the potential for enhanced anticancer efficacy is significant. With few therapeutic alternatives available, this approval presents a lifeline for many bladder cancer patients. Clinical trial outcomes also continue to capture attention. Eli Lilly's Nectin-4 targeting ADC showed promising results in advanced urothelial cancer, positioning itself as a potential competitor to Padcev. This innovation in ADC technology demonstrates the industry's relentless pursuit of targeted therapies that can revolutionize treatment paradigms. Bristol Myers Squibb's mezigdomide offers another example by showing a 52% reduction in progression risk for relapsed or refractory multiple myeloma patients, emphasizing the focus on addressing specific molecular pathways. In the realm of bispecific antibodies, Phanes Therapeutics' CLDN18.2/CD47 targeting therapy reported encouraging Phase 2 results in metastatic pancreatic ductal adenocarcinoma. These antibodies' ability to simultaneously engage multiple targets enhances their therapeutic efficacy against stubborn cancers, broadening the horizon for treatment possibilities. Meanwhile, Replimune's resubmission of its RP1 melanoma Biologics License Application (BLA) highlights the intricate dance between drug development and regulatory processes amid organizational shifts at the FDA. Such efforts reflect the continual adaptation required within the industry to navigate complex regulatory landscapes. On the funding front, Psilera's successful $8.8 million seed round indicates growing interest in psychedelic therapies for neurological conditions. Similarly, Reprogram Biosciences raised $6 million for its AI-driven cell reprogramming oncology platform, illustrating how artificial intelligence is becoming integral to advancing drug discovery and development. However, not all updates were positive. Agios Pharmaceuticals faced setbacks as their pyruvate kinase activator failed a Phase 2b trial for lower-risk myelodysplastic syndromes, serving as a sobering reminder of the inherent risks involved in drug development. Dizal Pharma emerges as a beacon of hope in lung cancer treatment following Takeda's EGFR exon 20 drug setback. By challenging existing treatments with promising small molecule data, Dizal exemplifies precision medicine's role in redefining oncology protocols—offering personalized patient options that could set new standards in treatment efficacy. The issue of drug pricing remains contentious, particularly highlighted by an AARP analysis showing an 81% increase post-launch prices stateside compared to a 13% decrease abroad. This disparity raises critical questions about achieving equitable access across markets amid Medicare negotiations and global pricing strategies like "most favored nation" policies. Regulatory updates continue with Johnson & Johnson's Tremfya label expansion stateside and AbbVie's EU extension for Venclyxto—moves that reflect efforts to maximize therapeutic reach and commercial viability across diverse geographies. Finally, Gilead Sciences' decision to discontinue its lead rheumatoid arthritis drug from MiroBio underscores ongoing challenges within emerging fields like BTLA agonists—a reminder of both innovation's promise and its perilous nature when faced with unproven therapeutic avenues. As these varied developments unfold, they collectively signal an era characterized by rapid scientific innovation and strategic collaborations across geographies alongside evolving regulatory landscapes—all driving towards enhanced patient care through more effective treatments globally. This concludes today's insights from Pharma Daily—a world where dynamic change continues reshaping healthcare delivery standards towards unprecedented possibilities for patient outcomes worldwide. Thank you for joining us; stay tuned for more updates on tomorrow's horizon-shaping advancements.Support the show

Editor-in-Chief of the Archives of Disease in Childhood, Dr Nick Brown, and Senior Editor of ADC, Dr Rachel Agbeko, bring you the monthly Atoms - the highlights of the June 2026 issue. Read it on the Archives of Disease in Childhood website: https://adc.bmj.com/content/111/6/i Please listen to our regular podcasts and subscribe in Apple Podcasts, Google Podcasts, Stitcher and Spotify to get episodes automatically downloaded to your phone and computer. And if you enjoy the podcast, please leave us a review at https://podcasts.apple.com/gb/podcast/adc-podcast/id333278832 

From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilson Family Chair at the Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School, both in Boston, Massachusetts.In this episode, Dr Matulonis was joined by Meghan E. Shea, MD, an attending medical oncologist and ambulatory medical director and disease program leader for medical oncology at Beth Israel Deaconess Medical Center in Boston. Together, they explored the current landscape of cervical cancer, from the urgent need for expanded vaccination and screening to the evolving role of immunotherapy and antibody-drug conjugates (ADCs) across disease settings.Dr Shea opened by addressing the epidemiology of cervical cancer, noting that despite decades of progress, rates are now plateauing and rising among women under 50 years of age. She identified 3 interrelated drivers of this trend: declining rates of routine gynecologic screening, inconsistent uptake of human papillomavirus (HPV) vaccination, and persistent high-risk HPV infections, particularly HPV 16 and 18, which are responsible for most cases. The conversation then turned to the effect of immunotherapy on cervical cancer treatment. Dr Shea traced the evolution of pembrolizumab (Keytruda) from its initial 2018 approval as a single agent in recurrent/metastatic disease to its more recent integration into the frontline setting. The phase 3 KEYNOTE-A18 trial (NCT04221945) demonstrated that adding pembrolizumab to standard weekly cisplatin-based chemoradiation significantly improved outcomes for patients with locally advanced disease. Although responses to immunotherapy, when they occur, are often durable, Dr Shea acknowledged that response rates remain lower than anticipated for a virally driven malignancy, underscoring the need for novel combinations and a deeper understanding of resistance mechanisms. Drs Matulonis and Shea both agreed that immunotherapy combined with ADCs represents one of the most compelling directions for the field, with phase 2 data for sacituzumab tirumotecan plus pembrolizumab generating interest ahead of anticipated phase 3 results.On the ADC front, Dr Shea reviewed the 2 agents in this class that are currently FDA-approved for cervical cancer. Tisotumab vedotin-tftv (Tivdak) offers the advantage of biomarker-independent use, though its requirement for ophthalmologic monitoring at every treatment visit creates real-world access challenges outside major academic centers. Trastuzumab deruxtecan-nxki (Enhertu), approved in the HER2 immunohistochemistry 3+ setting based in part on the results of the phase 2 DESTINY-PanTumor02 trial (NCT04482309), has generated robust response rates but is most likely to benefit patients with adenocarcinoma. Dr Shea also highlighted additional targets under investigation, including Trop-2, Nectin-4, and B7-H4, with multiple phase 3 trials ongoing in both the frontline and recurrent settings.The discussion closed with a look at the locally advanced disease landscape, where the NRG Oncology cooperative group is conducting a phase 3 trial to evaluate whether integrating the neoadjuvant carboplatin/paclitaxel regimen from the INTERLACE trial (NCT01566240) with the pembrolizumab-based regimen from KEYNOTE-A18 can further improve outcomes and reduce the morbidity associated with brachytherapy. Dr Shea expressed optimism about this question, citing preliminary experience suggesting that neoadjuvant chemotherapy may reduce the need for invasive radiation techniques.

Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Erika Hamilton from the Sarah Cannon Cancer Research Institute to discuss the latest advancements in breast cancer treatment following ESMO Breast 2026. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ We dived into key studies and recent FDA approvals, including: The exciting approval of Vepdegestrant from the VERITAC-2 study for ESR1-mutated breast cancer. The importance of ovarian function suppression in premenopausal patients, even with the advent of oral SERDs. Updates on HER2-positive disease treatments, including the newly approved T-DXd in neoadjuvant settings and the implications of de-escalation strategies. Insights from the SATEEN and BRE-354 studies on the use of antibody-drug conjugates (ADCs) after previous ADC treatments. A look at the Dato-DXd and Sacituzumab in frontline triple-negative breast cancer and how to choose between them. Join us as we unpack these critical findings and their implications for clinical practice. Don't forget to check out our other episodes for more treatment algorithms and conference highlights. Stay tuned for ASCO 2026, and remember, we are the Oncology Brothers! #ESMO2026, #ESR1mutation, #BreastCancerResearch, #PrecisionMedicine, #OncologyBrothers

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of noteworthy advancements and challenges that are shifting the landscape of drug development and patient care. Starting with AstraZeneca and Daiichi Sankyo, their Trop2-directed antibody-drug conjugate, Datroway, has secured FDA approval for first-line treatment in triple-negative breast cancer. This form of cancer is notoriously aggressive and offers limited treatment options, making this approval a significant milestone. It positions Datroway as a key player in the ADC market targeting TNBC, highlighting the increasing role of antibody-drug conjugates in oncology. This advancement not only expands therapeutic options for patients but also emphasizes the growing importance of ADCs in effectively targeting cancer cells while sparing healthy tissues. In another exciting development, Merck and Kelun Biotech have reported on their SAC-TMT ADC, which when paired with Keytruda, shows a profound impact on PD-L1-positive non-small cell lung cancer patients. Their combination therapy demonstrated a remarkable 65% reduction in disease progression or death compared to Keytruda alone. Presented at the ASCO annual meeting, these findings could potentially revolutionize first-line treatments for NSCLC, further underscoring the promising therapeutic potential of combining ADCs with immunotherapies. However, AstraZeneca faced a setback with a novel breast cancer drug as an FDA advisory committee recommended against its approval. Interestingly, the European Medicines Agency provided a favorable opinion, illustrating the divergent regulatory landscapes across continents. Such discrepancies highlight the complex regulatory environment pharmaceutical companies must navigate and could influence strategic decisions regarding market focus. On the legal front, Eli Lilly is embroiled in controversy over an alleged $200 million rebate fraud scheme involving its diabetes drug, Trulicity. This situation sheds light on ongoing issues within pharmaceutical distribution channels and raises questions about compliance and oversight mechanisms necessary to prevent such financial misconduct. Meanwhile, industry dynamics continue to evolve as AbbVie announced workforce reductions in its Allergan Aesthetics unit. This move reflects broader trends where companies streamline operations to prioritize core competencies and promising therapeutic areas. From a regulatory perspective, Maat Pharma's decision to seek re-examination for its graft-versus-host disease medication underscores the iterative nature of drug approval processes. Persistence in addressing regulatory feedback remains crucial as companies strive for successful market entry. In obesity management, Novo Nordisk's oral GLP-1 receptor agonist, Wegovy, gains traction as a convenient treatment option. The shift towards oral medications could significantly improve patient adherence and outcomes by offering an easier alternative to injections. Biogen's decision to terminate its collaboration with Denali Therapeutics after unsuccessful phase 2 trials for a Parkinson's disease candidate highlights the inherent risks in neurological drug development. Rigorous clinical evaluation remains essential to ensure efficacy before advancing therapies further. Despite these advancements, challenges persist as Biogen and Denali's BIIB122 failed in phase 2b trials for idiopathic Parkinson's disease. This underscores the complexity of neurological disorders and emphasizes the need for continued innovation targeting LRRK2 kinase inhibitors. In the realm of CAR-T therapies, Novartis' T-Charge platform faces competition from emerging in vivo technologies. This competitive landscape demonstrates rapid evolution within cell therapy domains, aiming to enhance efficacy and accessibility for patients. Meanwhile, strategic mergers and acquisitions continue as Liminatus Pharma acquires CAR-T biotech Innocsai for $320 million, underscoring sustained interest in oncology cell therapies. Switching gears to Eli Lilly's recent Phase 3 TRIUMPH-1 trial results for retatrutide, they reveal promising weight loss outcomes comparable to bariatric surgery. As a triple hormone receptor agonist targeting GLP-1, retatrutide holds significant potential in addressing obesity—a condition with profound public health implications. Medtronic's acquisition of SPR Therapeutics to enhance its chronic pain portfolio reflects a focus on minimally invasive treatments. Financially, Research Alliance III raised $75 million through a SPAC IPO targeting mergers with China-based biotech firms, signaling increased global collaboration within the sector. Dandelion Health's $14 million Series A funding aims to advance clinical intelligence platforms that could transform drug development through data analytics. Finally, Moderna's mRNA-based flu vaccine is set for review by the FDA's vaccine advisory committee after overcoming initial regulatory hurdles. This scrutiny highlights ongoing challenges faced by novel vaccine technologies within rigorous regulatory environments. In summary, these developments illustrate an industry at the forefront of scientific innovation while grappling with regulatory complexities and operational challenges. From antibody-drug conjugates and immunotherapy combinations to gene editing and advanced cell therapies, there's a clear commitment to improving patient outcomes through novel scientific approaches. As these trends evolve, they promise to redefine treatment landscapes across various therapeutic areas—offering new opportunities for scientific advancements and enhanced patient care worldwide.Support the show

Discuto a decisão que o STF deu às ADI's 7612 e 7631 e à ADC n. 92 que tratavam da lei n. 14.611/23. Discuto os fundamentos das ações e as razões pelas quais o STF declarou válida a lei. Falo sobre a conformidade desta lei também com a Convenção n. 100 da OIT e com leis de outros países.

ADC talks Ketel Marte, Ryne Nelson, and his big hit last night.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry is currently navigating a pivotal era marked by a blend of scientific innovation, regulatory shifts, and intriguing clinical trial results. A key regulatory upheaval unfolds as the FDA faces leadership changes. The recent departures of key figures from both the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER) underscore a period of uncertainty. With former commissioner Marty Makary stepping down, concerns arise about how these changes might affect drug approvals and regulatory guidance at such a crucial time in the industry. Turning to clinical trials, Regeneron has experienced a setback as its lag-3 inhibitor failed to surpass Merck's Keytruda in phase 3 melanoma studies. This marks Regeneron's second significant late-stage failure within a year, prompting analysts to reassess its strategic direction in oncology. In parallel, Regeneron has inked a $2.3 billion agreement with Parabilis Medicines to develop an advanced antibody-drug conjugate (ADC)-like therapy. The goal is to enhance targeting capabilities by improving binding to complex target sites, which could revolutionize ADC technology. Similarly, BioMarin's substantial investment in Inozyme's enzyme replacement therapy faced hurdles after falling short on one of two primary endpoints in a phase 3 trial for a rare genetic disorder. Such outcomes highlight the inherent risks and high stakes involved in late-stage drug development. Yet, innovation continues to drive progress. Vincentage Pharma's oral GLP-1 agonist has demonstrated a promising mean weight loss of 12.4% over a year, positioning it as a competitor to Eli Lilly's Orforglipron in the burgeoning Chinese market. This reflects the global pursuit to harness GLP-1 receptor agonists in tackling metabolic disorders and obesity. Ipsen has made strides with its long-acting neurotoxin for aesthetic applications, advancing into phase 3 trials following encouraging phase 2 results that showed significant improvements in frown lines lasting up to 24 weeks post-treatment. This progress suggests robust competition against established players like Botox. Meanwhile, Merck and Kelun-Biotech have successfully completed a phase 3 trial with their trop2-directed ADC sacituzumab tirumotecan (SAC-TMT) for endometrial cancer, achieving primary endpoints and paving the way for further regulatory submissions. Such advancements emphasize ADC technology's growing importance in oncology therapeutics. Broad industry trends reflect strategic investments, exemplified by Boston Scientific's $1.5 billion investment in Mirus and an option to acquire its transcatheter aortic valve replacement system—highlighting continued interest in high-growth medtech sectors. In another notable development, Daiichi Sankyo and AstraZeneca have reached a milestone with their ADC Enhertu, securing dual FDA approvals for early breast cancer treatment. These approvals underscore Enhertu's potential to expand treatment options for patients at an early disease stage, potentially altering standard treatment protocols. On the regulatory front, AstraZeneca has secured FDA approval for baxdrostat—an aldosterone synthase inhibitor developed through its acquisition of CinCor Pharma—demonstrating strategic investment in innovative cardiovascular therapies aligned with ambitious revenue goals. However, challenges persist as demonstrated by Amgen's Tavneos being linked to fatalities across Japan and the U.S., raising significant concerns about data integrity and pharmacovigilance. In contrast, Revolution Medicines' RAS inhibitor doubled survival rates in phase 3 pancreatic cancer trials. This breakthrough positions Revolution as an emerging leader in oncology therapeutics amidst fierce competition from companies aiming to improve drug tolerability and extend survival benefits. These narratives paint a picture of an industry poised for transformation—balancing scientific breakthroughs against regulatory challenges and financial pressures. As therapeutic modalities evolve—from oral biologics to advanced ADCs—the sector is set on course for substantial impacts on patient care and drug development pipelines. In summary, the pharmaceutical and biotech industries' focus on advancing therapeutic options through scientific innovation while navigating complex regulatory landscapes underscores an ongoing commitment to addressing unmet medical needs through new drug classes and targeted therapies. These efforts highlight trends toward personalized medicine and precision oncology that are likely to shape future trajectories in these dynamic fields.Support the show

In this episode of the Crack House Chronicles True Crime Podcast Donnie and Dale discuss the disappearance of Leanne Green. 17 year old Leanne Martha Leanne Green was picked up by her brother Lawson from her work at the Holiday Inn on April 15, 1987 in Dickson TN. They ran out of gas about a 1/2 mile later. A family stopped to help and Lawson rode with them to get gas. They were gone less than 10 minutes. She was gone when they returned. Her purse and the car keys were sitting on the seat of the unlocked car and there were no signs of a struggle. https://www.crackhousechronicles.com/ https://linktr.ee/crackhousechronicles https://www.tiktok.com/@crackhousechronicles https://www.facebook.com/crackhousechronicles Check out our MERCH! https://www.teepublic.com/user/crackhousechronicles SOURCES: https://www.yahoo.com/news/leanne-green-case-shattered-dickson-100152693.html https://charleyproject.org/case/martha-leanne-green https://www.reddit.com/r/UnresolvedMysteries/comments/drbv4h/the_disappearance_of_martha_leanne_green/ https://www.google.com/search?client=firefox-b-1-d&hs=sbZ&sca_esv=74f761a989b9a07f&sxsrf=ANbL-n5cD4dIyuTFttcKJijBYOv-p_B9IQ:1779028552694&udm=7&fbs=ADc_l-aN0CWEZBOHjofHoaMMDiKpmAsnXCN5UBx17opt8eaTX5ijYCyJdSZFM4mewRGuivYYa3mYl0ctDuDplBAp7RpJJiertViLIk7lwzDfFJvD79peka0NjzC5Fx4T6srURfKtb_0GUYremVy9HofmP0FCn_uKHmxhARKhXQ0MgMqEDoWaMXAzYRQKTe8ElbKXMe0y9u1uOPH3M_RVcCbdzjQCZetVeg&q=leanne+green+youtube&sa=X&ved=2ahUKEwiz2LbnxcCUAxV45ckDHb4tH_0QtKgLegQIFhAB&biw=1366&bih=635&dpr=1#fpstate=ive&vld=cid:27bb5a9d,vid:XIfWatTfk5o,st:0  

Dr. Mayank Gandhi, CEO of NEOK Bio, discusses the company's work on bispecific antibody drug conjugates and the limitations of conventional ADCs, which target a single antigen. Using a bispecific antibody to target two unique antigens on a tumor can address the shortcomings of earlier approaches by improving delivery of the toxic payload, overcoming tumor heterogeneity, and reducing off-target toxicity.  NEOK has drugs in development for prostate cancer, and lung, head, neck, and gastrointestinal tumors. The trend for ADCs is toward multi-specific and multi-payload drugs, though Mayank warns it is not a simple task to go from one to many in designing these drug conjugates. Mayank explains, "There have been a lot of advancements in the last couple of decades, and especially the last few years, in various modalities in the treatment of hematological cancers, as well as to a certain degree in solid tumors. However, for many, many solid tumors, there's still a high unmet need given the still significant outcome, poor outcomes that patients experience, particularly with patients having metastatic disease across a variety of solid tumors. Now, if you look at specific modality like ADC or antibody drug conjugates, which is where NEOK Bio is, there's been a renaissance, if you will, with this modality in the last five to six years, particularly after the approval of a drug called Enhertu, which targets HER2 mutation. Now, many ADCs have been approved with different payloads. And so definitely that's made a dent in a variety of tumors, particularly in hematological cancers and select solid tumors as well."   "Conventional ADCs thus far target one antigen or one target on a tumor. So it's an antibody-based approach. The antibody is typically pursuing one specific antigen that's usually an antigen that's expressed on tumors selectively versus normal tissue or normal cells. And then you have a linker and a payload, usually a toxic payload that's conjugated via a linker to the antibody. So that's an antibody drug conjugate construct."   "Thus far, all the ADCs approved have been targeting only one antigen with a couple of different payloads. And so our bispecific approach is targeting two different antigens. If we use a bispecific antibody that targets two unique antigens on the tumor, we have more than one place that a potential antibody can bind and deliver the toxic payload. And then we have made some very significant improvements or changes in the antibody itself." #NEOKBio #DrugDevelopment #Innovation #AntibodyDrugConjugates #ADC #Oncology #Biotech#Oncology #SolidTumors #BispecificADC #CancerResearch #TranslationalResearch #MedicalOncology #HematologyOncology #ClinicalTrials #Biotech #Pharma #DrugDevelopment #PrecisionOncology #TumorMicroenvironment #TargetedTherapy NEOKBio.com Download the transcript here

Dr. Mayank Gandhi, CEO of NEOK Bio, discusses the company's work on bispecific antibody drug conjugates and the limitations of conventional ADCs, which target a single antigen. Using a bispecific antibody to target two unique antigens on a tumor can address the shortcomings of earlier approaches by improving delivery of the toxic payload, overcoming tumor heterogeneity, and reducing off-target toxicity.  NEOK has drugs in development for prostate cancer, and lung, head, neck, and gastrointestinal tumors. The trend for ADCs is toward multi-specific and multi-payload drugs, though Mayank warns it is not a simple task to go from one to many in designing these drug conjugates. Mayank explains, "There have been a lot of advancements in the last couple of decades, and especially the last few years, in various modalities in the treatment of hematological cancers, as well as to a certain degree in solid tumors. However, for many, many solid tumors, there's still a high unmet need given the still significant outcome, poor outcomes that patients experience, particularly with patients having metastatic disease across a variety of solid tumors. Now, if you look at specific modality like ADC or antibody drug conjugates, which is where NEOK Bio is, there's been a renaissance, if you will, with this modality in the last five to six years, particularly after the approval of a drug called Enhertu, which targets HER2 mutation. Now, many ADCs have been approved with different payloads. And so definitely that's made a dent in a variety of tumors, particularly in hematological cancers and select solid tumors as well."   "Conventional ADCs thus far target one antigen or one target on a tumor. So it's an antibody-based approach. The antibody is typically pursuing one specific antigen that's usually an antigen that's expressed on tumors selectively versus normal tissue or normal cells. And then you have a linker and a payload, usually a toxic payload that's conjugated via a linker to the antibody. So that's an antibody drug conjugate construct."   "Thus far, all the ADCs approved have been targeting only one antigen with a couple of different payloads. And so our bispecific approach is targeting two different antigens. If we use a bispecific antibody that targets two unique antigens on the tumor, we have more than one place that a potential antibody can bind and deliver the toxic payload. And then we have made some very significant improvements or changes in the antibody itself." #NEOKBio #DrugDevelopment #Innovation #AntibodyDrugConjugates #ADC #Oncology #Biotech#Oncology #SolidTumors #BispecificADC #CancerResearch #TranslationalResearch #MedicalOncology #HematologyOncology #ClinicalTrials #Biotech #Pharma #DrugDevelopment #PrecisionOncology #TumorMicroenvironment #TargetedTherapy NEOKBio.com Listen to the podcast here

What has competition enforcement looked like in Italy and Portugal over the past year? Saverio Valentino, Board Member of the Italian Antitrust Authority, joins Jaclyn Phillips to discuss AGCM's 2025 enforcement record, an ongoing digital sector investigation into Meta, and a whistleblower platform that has generated over 600 complaints since 2023. Next, Nuno Cunha Rodrigues, President of the Portuguese Competition Authority, speaks with Jeny Maier about a creative hospital merger remedy, AdC's research on AI and competition, and a consumer outreach initiative that took the authority beyond Lisbon. Listen to this episode to hear how two of Europe's most active competition agencies are approaching enforcement and advocacy in 2026. With special guests: Saverio Valentino, Board Member, AGCM (Italian Antitrust Authority) and Nuno Cunha Rodrigues, President, AdC (Portuguese Competition Authority) Related Links: Italian Antitrust Authority (AGCM) Portuguese Competition Authority (AdC) Hosted by: Jaclyn Phillips, Proskauer Rose and Jeny Maier, Axinn, Veltrop & Harkrider